VistaPath Biosystems
VistaPath Biosystems develops the Sentinel platform, an AI-powered automated tissue grossing system that uses computer vision to photograph, measure, and document pathology specimens. It serves commercial labs, hospitals, CROs, and life sciences companies via hardware placement and per-sample usage pricing.
- Company typePrivate
- Founded2017
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What VistaPath Biosystems does
VistaPath Biosystems is a privately held medical-technology company founded in 2017 and headquartered in Cambridge, Massachusetts. The company develops the Sentinel platform, an AI-powered automated tissue grossing system for anatomical pathology laboratories. Sentinel uses computer vision and machine learning to photograph, measure, and document tissue samples in under one second, generating gross reports that the company reports are produced 90%+ faster than manual methods with 43% greater accuracy. The platform includes modular add-ons — Link for workflow management, Merge for multi-vial cassette consolidation, Confirm for chain-of-custody and automated QA, and Consult for remote specialist collaboration — that extend coverage from grossing through digital sign-out. The system is ISO 27001 certified and FDA 21 CFR Part 11 compliant, and integrates with laboratory information systems (LIS) and EMR data.
VistaPath serves commercial pathology laboratories, hospital-based pathology departments, contract research organizations, and life sciences companies. Named customers and validation partners include PathGroup (12-unit deployment at its centralized Nashville, TN laboratory), Freedom Pathology Laboratories (Savannah, GA), and PathAI. The company sells through direct enterprise field sales supplemented by strategic partnerships and a demo-request channel for mid-market labs.
The business model combines hardware placement (sale or lease of Sentinel units) with usage-based per-sample billing, with VistaPath retaining responsibility for ongoing platform upkeep and maintenance. Pricing is quote-based and not publicly disclosed. The company has raised approximately $8.9M in disclosed venture funding from Moxxie Ventures, First Star Ventures, NextGen Venture Partners, Cota Capital, and ValueStream Ventures. Leadership comprises CEO and co-founder Tim Spong (15-year histotechnologist), COO and co-founder Ben Burley, CTO Jacob Guggenheim (MIT PhD, Human-Machine systems), and VP of Sales and Marketing J. Fernando Corredor.
VistaPath Biosystems firmographics
Firmographics- Name
- VistaPath Biosystems
- Legal name
- Vistapath Biosystems, Inc.
- Website
- https://vistapath.ai
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- VistaPath Biosystems develops the Sentinel platform, an AI-powered automated tissue grossing system that uses computer vision to photograph, measure, and document pathology specimens. It serves commercial labs, hospitals, CROs, and life sciences companies via hardware placement and per-sample usage pricing.
- Ownership category
- akta.pro rank
VistaPath Biosystems industry classification
Industry- Product category
- Digital Pathology Automation Software
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)
Keywords
Where VistaPath Biosystems is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
VistaPath Biosystems business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure
Revenue model
- Per-Sample Usage Billing: Labs pay per sample processed through the Sentinel platform, providing a scalable, consumption-based revenue model. Vistapath manages all platform upkeep and maintenance.
- Hardware Device Sales: Sale or lease of Sentinel hardware units to laboratories, with Vistapath managing ongoing platform maintenance.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Usage-based | Pay-as-you-go | Per-sample pricing model |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
VistaPath Biosystems product offering
Product offeringCore offering
VistaPath Biosystems develops and sells the Sentinel automated tissue grossing platform, an AI-powered computer vision system that photographs, measures, and documents anatomical pathology tissue samples for clinical and research laboratories. The platform integrates with laboratory information systems (LIS) and EMR data via the proprietary SentinelOS and is sold alongside modular add-ons (Sentinel Link, Merge, Confirm, and Consult) that handle workflow management, multi-vial cassette consolidation, chain-of-custody QA, and remote specialist consultation. Customers include commercial pathology laboratories, hospital pathology departments, contract research organizations (CROs), and life sciences companies.
Product overview
Vistapath offers the Sentinel platform, an end-to-end digital grossing solution comprising a core automated tissue grossing platform plus modular add-ons. The main Sentinel product provides AI-powered tissue grossing with computer vision and automation. The Sentinel ecosystem includes Link (workflow management), Merge (cassette consolidation), Confirm (chain of custody/QA), and Consult (remote collaboration) modules, all designed to modernize pathology labs by delivering higher quality, efficiency, and consistency across critical lab processes.
Differentiator
Problem solved
Functional benefit
Brands
- Sentinel: The world's first automated tissue grossing platform that uses AI and computer vision to optimize pathology workflows, generating gross reports faster and more accurately than traditional methods.
Products and services
- Sentinel Automated Tissue Grossing Platform End-to-end AI-powered automated tissue grossing platform that uses computer vision to receive, assess, photograph, measure, and document tissue specimens. Measures samples in under one second, generates gross reports 90%+ faster than manual methods, and integrates with laboratory information systems (LIS) and EMR data; targets commercial pathology labs, hospital pathology departments, CROs, and life sciences research laboratories.
- Sentinel Link Secure, web-based platform that lets lab assistants image and document specimens at the bench with the Sentinel device, generating structured gross reports in real time for review and approval by certified grossing personnel or pathologists.
- Sentinel Merge AI-powered feature that consolidates specimens from multiple vials of tissue into a single unified cassette using AI measurement and tracking, reducing labor costs, turnaround times, and downstream reagent usage while preserving reimbursement.
- Sentinel Confirm Automated quality assurance and chain-of-custody module that provides time-stamped events and embedded QA, ensuring complete, consistent case context for pathologists during digital sign-out.
- Sentinel Consult Real-time remote collaboration module that enables labs to securely live broadcast cases via Sentinel Workspace for specialist consultation, staff training, and practice standardization without travel.
Quantifiable outcome
- 90%+ faster end-to-end grossing process
- +3 more outcomes
Companies that use VistaPath Biosystems
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
VistaPath Biosystems technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
AI capability5 records
Feature6 records
VistaPath Biosystems partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and flagship.
- Freedom Pathology LaboratoriescoreFreedom Pathology Laboratories in Savannah, Georgia deployed the Sentinel platform. The deployment enhanced grossing process efficiency, reduced errors, and improved specimen handling consistency. The deployment demonstrated minimal onboarding requirements for technicians.
- PathGroupflagshipPathGroup deployed 12 Sentinel AI-powered grossing platforms at their centralized laboratory in Nashville, TN. This major enterprise deployment strengthens PathGroup's commitment to innovation and diagnostic precision. The partnership represents an important step in modernizing pathology grossing workflows at scale.
- PathAIcoreVistaPath and PathAI collaborated to validate the Sentinel automated tissue grossing platform in a clinical setting. PathAI validated the Sentinel in their clinical workflow, establishing it as a validated AI-powered grossing solution. This partnership charted the course for broader clinical market adoption following FDA and ISO27001 compliance.
- Gestalt DiagnosticscoreCollaboration combining VistaPath's Sentinel automated tissue grossing platform with Gestalt's AI Requisition Engine (AIRE) to advance pathology digitization. The partnership integrates automated grossing with AI-powered accessioning to improve front-end laboratory workflow speed and accuracy.
Scale indicators4 records
Recent moves6 records
Expansion highlights4 records
VistaPath Biosystems competitors and assessment
Company assessmentDirect peers
- PathAI: AI-powered digital pathology platform serving pharma, diagnostic labs, and pathology practices. Directly comparable as a clinical AI pathology vendor and is both a current VistaPath partner and a potential competitor in the same pathology AI category.
- Gestalt Diagnostics: Provides AI-driven pathology workflow and requisition software (PathFlow, AIRE) for hospital and commercial labs. Directly comparable as a pathology digitization partner and VistaPath's existing integration collaborator for front-end accessioning workflows.
- Proscia: Digital pathology software platform with AI applications for diagnostic and research pathology labs. Comparable as a software-led pathology workflow vendor targeting similar commercial lab and biopharma customers with an overlapping AI/computer-vision stack.
- Ibex Medical Analytics: AI-powered cancer diagnostics platform deployed in pathology labs worldwide for clinical decision support. Directly comparable as an AI pathology vendor serving commercial and hospital labs, with overlapping computer-vision and lab workflow integration requirements.
- Aiforia: AI image analysis platform for pathology and other life-science microscopy. Comparable as an AI computer-vision vendor to pathology and life-sciences customers, with overlapping use cases in tissue-based diagnostics and research workflows.
Broad incumbents
- Roche (Ventana): Global leader in tissue diagnostics through its Ventana Digital Pathology portfolio, serving the same hospital and commercial lab customers. Comparable as a broad incumbent with much larger scale that could enter or bundle automated grossing offerings.
- Philips Digital Pathology: Operates the IntelliSite Pathology Solution for whole-slide imaging and digital workflows in hospital pathology. Comparable as a broad incumbent digital pathology vendor with established enterprise sales reach into VistaPath's target accounts.
- Leica Biosystems: Major supplier of histology instruments, consumables, and digital pathology solutions (Aperio) used by hospital and commercial labs. Comparable as a broad incumbent with deep relationships in the same grossing and histology workflow VistaPath targets.
Emerging players
- Akoya Biosciences: Spatial biology and multiplex tissue analysis platform with growing pathology lab footprint. Comparable as an emerging tissue-analysis vendor pursuing pathology and life-sciences customers with adjacent AI and imaging capabilities.
- Owkin: AI-driven pathology and biopharma analytics company serving research and clinical pathology use cases. Comparable as an emerging player in AI-enabled tissue analysis with overlapping life-sciences and pathology customers.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks7 records
Key highlights7 records
Customer concentration
VistaPath Biosystems social profiles
Digital presenceVistaPath Biosystems compliance and trust
Trust signalCompliance2 records
VistaPath Biosystems financial estimates
Financial estimateRevenue estimate
Valuation estimate
VistaPath Biosystems leadership team
Management profileNumber of profiles
Profiles4 records
VistaPath Biosystems funding detail
Funding detailFunding overview
Funding rounds7 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
VistaPath Biosystems M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about VistaPath Biosystems
What does VistaPath Biosystems do?
VistaPath Biosystems develops and sells the Sentinel automated tissue grossing platform, an AI-powered computer vision system that photographs, measures, and documents anatomical pathology tissue samples for clinical and research laboratories. The platform integrates with laboratory information systems (LIS) and EMR data via the proprietary SentinelOS and is sold alongside modular add-ons (Sentinel Link, Merge, Confirm, and Consult) that handle workflow management, multi-vial cassette consolidation, chain-of-custody QA, and remote specialist consultation. Customers include commercial pathology laboratories, hospital pathology departments, contract research organizations (CROs), and life sciences companies.
Is VistaPath Biosystems a public or private company?
VistaPath Biosystems is a private company. It is classified as venture growth investor backed and is currently operating.
When was VistaPath Biosystems founded?
VistaPath Biosystems was founded in 2017. It employs 11 to 50 people.
Where is VistaPath Biosystems based?
VistaPath Biosystems is headquartered in Cambridge, United States, in the North America region.
How does VistaPath Biosystems make money?
Two revenue lines are on record. Per-Sample Usage Billing is the primary driver. The others are hardware Device Sales.
Who are VistaPath Biosystems's main competitors?
Direct peers on record are PathAI, Gestalt Diagnostics, Proscia, Ibex Medical Analytics and Aiforia. Broad incumbents are Roche (Ventana), Philips Digital Pathology and Leica Biosystems. Emerging players are Akoya Biosciences and Owkin.
Does VistaPath Biosystems have an API?
No public API is recorded for VistaPath Biosystems.
What industry is VistaPath Biosystems in?
VistaPath Biosystems's product category is Digital Pathology Automation Software. Its primary akta.pro industry code is HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 334516 and its SIC code is 3826.